alanine has been researched along with Bleeding in 11 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The 2 populations studied were as follows: (1) a cross-sectional study of 703 acute coronary syndrome (ACS) patients with myocardial infarction (MI) and unstable angina, and (2) a prospective study of 924 Caucasian patients from the OPUS (Orbofiban in Patients with Unstable coronary Syndromes)-TIMI-16 trial of the oral GPIIb/IIIa antagonist orbofiban." | 5.10 | Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease. ( Fitzgerald, A; Fitzgerald, DJ; Muckian, C; O'Byrne, A; O'Neill, A; Shields, DC, 2002) |
| " The relevance of circadian dosing time was investigated for chronotherapeutic optimization of SDX-102." | 1.33 | Circadian pharmacology of L-alanosine (SDX-102) in mice. ( Carrière, J; Crépin, D; Elliott, G; Guettier, C; Kanekal, S; Lévi, F; Li, XM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muckian, C | 2 |
| Fitzgerald, A | 2 |
| O'Neill, A | 1 |
| O'Byrne, A | 1 |
| Fitzgerald, DJ | 3 |
| Shields, DC | 3 |
| BORRELLI, F | 1 |
| DELLORUSSO, R | 1 |
| Li, XM | 1 |
| Kanekal, S | 1 |
| Crépin, D | 1 |
| Guettier, C | 1 |
| Carrière, J | 1 |
| Elliott, G | 1 |
| Lévi, F | 1 |
| Meyer, M | 1 |
| Dietzel, H | 1 |
| Kaetzel, R | 1 |
| Schmidt, D | 1 |
| Liebscher, K | 1 |
| Brennan, SO | 1 |
| Pruissen, DM | 1 |
| Rosendaal, FR | 1 |
| Gorter, JW | 1 |
| Garcia, AA | 1 |
| Kappelle, LJ | 1 |
| Algra, A | 1 |
| Ulrich, S | 1 |
| Brand, B | 1 |
| Speich, R | 1 |
| Oldenburg, J | 2 |
| Asmis, L | 1 |
| Sabatine, MS | 1 |
| Jang, IK | 1 |
| Chew, DP | 1 |
| Bhatt, DL | 1 |
| Sapp, S | 1 |
| Topol, EJ | 1 |
| Neuhaus, T | 1 |
| Hertfelder, HJ | 1 |
| Hess, L | 1 |
| Walger, P | 1 |
| Vetter, H | 1 |
| O'Connor, FF | 1 |
| Cannon, CP | 2 |
| Braunwald, E | 1 |
| Fitzgerald, AP | 1 |
| O'Neill, PA | 1 |
| Kenny, D | 1 |
| Moran, B | 1 |
| Byrne, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer[NCT03943966] | 73 participants (Actual) | Interventional | 2019-11-11 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alanine and Bleeding
| Article | Year |
|---|---|
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; A | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
3 trials available for alanine and Bleeding
| Article | Year |
|---|---|
Genetic variability in the extracellular matrix as a determinant of cardiovascular risk: association of type III collagen COL3A1 polymorphisms with coronary artery disease.
Topics: Alanine; Alleles; Angina, Unstable; Collagen; Collagen Type III; Coronary Disease; Cross-Sectional S | 2002 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists.
Topics: Alanine; Coronary Disease; Genotype; Glycoproteins; Hemorrhage; Humans; Myocardial Infarction; Myoca | 2002 |
6 other studies available for alanine and Bleeding
| Article | Year |
|---|---|
[PLASMA ENZYME BEHAVIOR (ASPARTIC AND ALANINE KETOGLUTARIC TRANSAMINASES) IN HEMORRHAGIC SUBJECTS].
Topics: Alanine; Alanine Transaminase; Aspartate Aminotransferases; Blood Chemical Analysis; Clinical Enzyme | 1963 |
Circadian pharmacology of L-alanosine (SDX-102) in mice.
Topics: Alanine; Animals; Antineoplastic Agents; Body Weight; Bone Marrow; Chronotherapy; Darkness; Gene Exp | 2006 |
Fibrinogen Leipzig II (gamma351Gly-->Ser and gamma82Ala-->Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain.
Topics: Adult; Afibrinogenemia; Alanine; Fibrinogen; Glycine; Haplotypes; Hemorrhage; Heterozygote; Humans; | 2007 |
Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin.
Topics: ABO Blood-Group System; Administration, Oral; Aged; Alanine; Anticoagulants; Arteries; Blood Protein | 2007 |
Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland.
Topics: Aged; Alanine; Amino Acid Substitution; Anticoagulants; Coumarins; Drug Hypersensitivity; Factor IX; | 2008 |
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment].
Topics: Aged; Alanine; Anticoagulants; Aortic Valve; Echocardiography; Factor IX; Heart Valve Prosthesis; He | 2001 |